Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
MORRIS PLAINS, N.J., Aug. 13, 2015 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU) today announced that it will host a conference call and live audio webcast on Thursday, August 20, 2015 at 10:00...
-
MORRIS PLAINS, N.J., Aug. 4, 2015 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU) today announced that the Office of Orphan Products Development of the U.S. Food and Drug Administration (FDA) has...
-
CHICAGO, June 2, 2015 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (Nasdaq:IMMU) today announced an interim analysis of a mid-stage clinical study showed that its first-in-class antibody-drug conjugate...
-
CHICAGO, June 2, 2015 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (Nasdaq:IMMU) today announced that sacituzumab govitecan, the Company's lead investigational antibody-drug conjugate (ADC), demonstrated...
-
CHICAGO, June 1, 2015 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (Nasdaq:IMMU) today announced that a majority of patients with heavily-pretreated, metastatic gastrointestinal cancers responded to...
-
CHICAGO, June 1, 2015 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (Nasdaq:IMMU) today announced that among 49 patients with metastatic triple-negative breast cancer (TNBC) evaluated for response to...
-
MORRIS PLAINS, N.J., May 26, 2015 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (Nasdaq:IMMU) today announced that the Company will present at Jefferies 2015 Global Healthcare Conference at 11:00 a.m....
-
MORRIS PLAINS, N.J., May 15, 2015 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (Nasdaq:IMMU) today announced that it has received notice from the U.S. Food and Drug Administration (FDA) designating as a...
-
MORRIS PLAINS, N.J., May 14, 2015 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (Nasdaq:IMMU) today announced that two of its five abstracts submitted to the 2015 Annual Meeting of the American Society of...
-
MORRIS PLAINS, N.J., May 12, 2015 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (Nasdaq:IMMU) today announced the issuance of U.S. Patent No. 9,028,833 for a new patent family "Dosages of immunoconjugates...